The science of Probiotics: A review Keith J Barrington

Probiotics

What are probiotics? “Live micro-organisms which when administered in adequate amounts confer a health benefit on the host” FAO WHO 2001

© International Pediatrics Research Foundation, Inc All Rights Reserved. Published by Lippincott Williams & Wilkins, Inc. 4 Figure 1. The Pioneer Gut Microbiota in Human Neonates Vaginally Born at Term-A Pilot Study. KARLSSON, CAROLINE; MOLIN, GORAN; CILIO, CORRADO; AHRNE, SIV Pediatric Research. 70(3): , September DOI: /PDR.0b013e318225f765 Figure 1. Bacterial incidence in healthy neonates vaginally born at term. Incidence of different bacterial groups in the fecal microbiota of neonates in their first 48 h of life, presented as percentage of total number of neonates (n = 79). Primers used for the qPCR analysis are indicated in Table 1.

29 prématurés <30 wk

The aggregate relative proportion of family-level faecal microbiota in 10 preterm infants at weeks 2 (A) and 4 (B) of life. Barrett E et al. Arch Dis Child Fetal Neonatal Ed doi: /archdischild Copyright © BMJ Publishing Group Ltd & Royal College of Paediatrics and Child Health. All rights reserved.

What is the source of the dysbiosis of the preterm infant? Vaginal colonization with Bifido & Lacto as pregnancy advances Often born by cesarian Exposed to antibiotics pre and postnatally Exposed to NICU flora Multiple procedures – Fed by tube – Aspiration – Intubation Less breast milk received

Collado MC, Delgado S, Maldonado A, Rodríguez JM: Assessment of the bacterial diversity of breast milk of healthy women by quantitative real-time pcr. Letters in Applied Microbiology 2009, 48(5): Table 2. Detection of bacterial DNA in the breast milk samples by quantitative real- time PCR technique (qRTi-PCR). Data are presented as log10 (genome equivalent ml−1) Bacterial groupsPrevalenceRangeMean ± SD Total bacteria50/505·05–7·766·03 ± 0·75 Staphylococcus group 50/501·30–5·563·55 ± 0·84 Bifidobacterium group 50/502·45–4·753·56 ± 0·53 Lactobacillus group50/502·61–4·503·74 ± 0·47 Enterococcus group38/501·20–4·852·56 ± 0·71 Streptococcus group 50/502·91–6·114·50 ± 0·81 Bacteroides group20/501·50–3·352·02 ± 0·55 Clostridium cluster XIVa–XIVb 48/502·27–4·853·32 ± 0·60 Clostridium cluster IV 2/501·07–2·121·60 ± 0·17

Newburg DS, Ruiz-Palacios GM, Morrow AL: Human milk glycans protect infants against enteric pathogens. Annu Rev Nutr 2005, 25(1): GlycoconjugatePathogenReferenceTypical concentration a GM1Labile toxin, cholera toxin(44)180 μg/liter GM3Enteropathogenic Escherichia coli (20)13 mg/liter Gb 3 Shiga toxin(36)100–150 μg/liter SulfatideHuman immunodeficiency virus(59)100 μg/liter Chondroitin sulfateHuman immunodeficiency virus(39)6 mg/liter LactadherinRotavirus(62)100 μg/liter MucinS-fimbriated E. coli(50)1 g/liter Mannosylated glycopeptideEnterohemorrhagic E. coli(2)60 mg/liter OligosaccharidesStreptococcus pneumoniae(1)0.2–10 g/liter Enteropathogenic E. coli(9)3 g/liter Listeria monocytogenes(6)3 g/liter Fucosylated oligosaccharidesCampylobacter jejuni Vibrio cholerae Stable toxin (46) (46) (41)1–25 mg/liter 1–25 mg/liter 40 μg/liter Macromolecule-associated glycans Noroviruses Pseudomonas aeruginosa (23) (26)370 mg/liter SialyllactoseCholera toxin(21)200 mg/liter E. coli(53, 57)200 mg/liter P. aeruginosa(10)200 mg/liter Aspergillus fumigatus conidia(3)200 mg/liter Influenza virus(13, 29)200 mg/liter Polyomavirus(52)200 mg/liter Helicobacter pylori(33)200

Siggers RH, Siggers J, Thymann T, Boye M, Sangild PT: Nutritional modulation of the gut microbiota and immune system in preterm neonates susceptible to necrotizing enterocolitis. The Journal of Nutritional Biochemistry 2011, 22(6):

Establishment and development of intestinal microbiota in preterm neonates FEMS Microbiology Ecology Volume 79, Issue 3, pages , 15 DEC 2011 DOI: /j x x/full#fem1261-fig-0001 Volume 79, Issue 3, x/full#fem1261-fig-0001

Fig.1 Neonatal bacterial colonization of the gut is determined by environmental factors (e.g. diet and rearing environment), combined with internal host influences (genetics and intrinsic gut characteristics). All these determinants contribute t... Malene S. Cilieborg, Mette Boye, Per T. Sangild Bacterial colonization and gut development in preterm neonates Early Human Development Volume 88, Supplement S41 - S49

Latest meta-analysis Wang Q, Dong J, Zhu Y: Probiotic supplement reduces risk of necrotizing enterocolitis and mortality in preterm very low-birth-weight infants: an updated meta-analysis of 20 randomized, controlled trials. J Pediatr Surg 2012, 47(1):

StudyParticipantsBirth weight or gestation Probiotic agentsPrimary outcomeJadad score ProbioticsPlacebo Kitajima H, 1997[30][30]4546<1500 gBifidobacteriaNEC; sepsis; mortality3 Dani C, 2002 [31][31]295290<33 wk or <1500 gLactobacillusNEC; sepsis; mortality4 Costalos C, 2003[32][32] wkSaccharomycesNEC; sepsis5 Bin-Nun A, 2005[33][33]7273<1500 gMixture a NEC; sepsis; mortality3 Lin HC, 2005 [34][34]180187<1500 gLactobacillus and bifidobacteria NEC; sepsis; mortality4 Manzoni P, 2006[35][35]3941<1500 gLactobacillusNEC; sepsis; mortality4 Mohan R, 2006[36] b[36] 2117<34 wk and <1500 gbifidobacteriaNEC4 Stratiki Z, 2007[37] b[37] 3831<34 wk and <1500 gbifidobacteriaNEC; sepsis; mortality5 Ke D, 2008 [38][38]9891<32 wkbifidobacteriaNEC4 Lin HC, 2008 [39][39]217 <34 wk and <1500 gLactobacillus and bifidobacteria NEC; sepsis; mortality5 Huang B, 2009 [40][40]9588<32 wk and <1500 gBifidobacteriaNEC3 Manzoni P, 2009[12][12]151168<1500 gLactobacillusNEC; sepsis; mortality5 Rougé C, 2009 [41][41]4549<32 wk and <1500 gLactobacillus and bifidobacteria NEC; sepsis; mortality5 Samanta M, 2009[42][42]9295<34 wk and <1500 gLactobacillus and bifidobacteria NEC; sepsis; mortality3 Underwood MA, 2009 [13][13]6129<34 wk and g Lactobacillus and bifidobacteria NEC5 Di M, 2010 [43][43]4135<32 wkBifidobacteriaNEC3 Mihatsch WA, 2010[14][14]9189<30 wk and <1500 gBifidobacteriaNEC; sepsis; mortality5 Ren B, 2010 [44][44]8070<33 wk and g BifidobacteriaNEC3 Braga TD, 2011[15][15]119112<1500 gLactobacillus and bifidobacteria NEC; sepsis; mortality5 Sari FN, 2011 [16][16]110111<33 wk or <1500 gLactobacillusNEC; sepsis; mortality5

Forest plots of probiotics in preterm infants (A, Effect of probiotics on NEC; B, Effect of probiotics on mortality; C, Effect of probiotics on sepsis).

Subgroup analyses Studies (no. in probiotics group/no. in placebo group) RR RR (95%CI)P RR I 2 Heterogeneity P Heterogeneity Model Bifidobacteria NEC8 (509/467)0.30 ( ) Fixed Mortality3 (174/166)0.74 ( ) Fixed Sepsis3 (174/166)0.84 ( ) Fixed Lactobacillus and Bifidobacteria NEC6 (714/689)0.33 ( ) Fixed Mortality5 (653/660)0.47 ( ) Random Sepsis5 (653/660)0.90 ( ) Random Lactobacillus NEC4 (595/610)0.37 ( ) Fixed Mortality4 (595/610)0.61 ( ) Fixed Sepsis4 (595/610)0.79 ( ) Random

Other recent meta-analyses Deshpande G, Rao S, Patole S, Bulsara M: Updated Meta-analysis of Probiotics for Preventing Necrotizing Enterocolitis in Preterm Neonates. Pediatrics 2010, 125(5): AlFaleh, Khalid; Anabrees, Jasim; Bassler, Dirk; AlKharfi, Turki: Probiotics for prevention of necrotizing enterocolitis in preterm infants Cochrane Database of Systematic Reviews. Issue 3, 2011.

Funnel plot to assess publication bias Analysis of effect of probiotic supplement on NEC risk including 20 studies; TEgger test = −1.12; 95% CI, −1.82 to 0.56; PEgger test =.278 >.05

Trial sequential analysis. Deshpande G et al. Pediatrics 2010;125:

Other RCTs 2 other RCTS have been recently presented, both examined the effects of ‘Saccharomyces boulardii’ : no effect shown in either study. Also: Rojas MA, Lozano JM, Rojas MX, et al: Prophylactic probiotics to prevent death and nosocomial infection in preterm infants. Pediatrics Multicenter RCT infants <2kg; primary outcome was survival without nosocomial sepsis (Columbia). NEC 8/372 probiotics 15/378 controle (L reuteri) 2 others in progress, or just completed, with a total of 2,400 enfants, – Costeloe angleterre, (PIP) primary outcome is sepsis, NEC or death (justification en partie ‘None of the studies has taken place in the UK’) – Tobin Australie (PROPREMS) primary outcome sepsis.

ProPrems Just finished and presented at EAPS Australian RCT of probiotics; a mixture of 2 bifidobacteria (infantis and lactis) and streptococcus thermophilus (ABCDophilus) 1100 babies randomized <1500g and <32 wk 4.4% NEC grade 2 or more in controls 2.2% NEC (grade 2 or more) with probiotics Slightly fewer serious infections

Meta-analysis Sans Manzoni 2009, sans les études de Saccharomyces

Our Abstract PAS 2013 Barrington K et al Design/Methods: Starting in July 2011 we have administered a preparation containing a mix of 4 bifidobacteria (b breve, bifidum, infantis and longum) and lactobacillus rhamnosus (Florababy (tm) holder of a Natural Product Number from Health Canada). Data on complications has been collected, and compared with the admissions to the NICU during the previous 12 months. Infants surviving for less than 7 days were eliminated. NEC stage 2 or greater was diagnosed by the presence of pneumatosis or other diagnostic findings on an abdominal radiograph, by an attending radiologist.

Mean (SD) or Percentage or N Pre- CohortProbiotic CohortSignificance N GA wk28.6 (2.2)29.2 (2.4)p=0.06 Birthweight, g1169 (379)1248 (362)p=0.07 NEC, N2413p<0.02 Deaths219p<0.05 Death or NEC3721p<0.004 Culture +ve sepsis (at least 1 episode) 22%19%NS Logistic regression analysis including terms for gestational age and being SGA. Probiotic administration remained significant, p=0.02, Odds Ratio 0.47 (95% CI 0.252, 0.887).

Abstract PAS 2013 Blood Culture positive sepsis was not affected by the introduction of probiotics, 22% of the infants had at least one episode prior to probiotics, 19% after the introduction of probiotics. No cases of sepsis caused by the probiotic organisms has been noted. Feeding tolerance, as measured by time to stopping TPN was shorter after the introduction of probiotics (11 d (SD10) vs 16 (SD 20), but this difference disappeared after correcting for gestational age and being SGA. Conclusions: A product, commercially available in North America with good quality control, when used in routine daily administration, was associated with a substantial and significant decrease in definite NEC without apparent adverse effect. Further studies of probiotics should compare different strains

Probiotics Probiotics are proven to reduce NEC and mortality. The preparation chosen should contain a Bifidobacterium or Lactobacillus Rhamnosus, and probably a mix of the two Good Quality Control of the preparation is essential Parents deserve the right to know about probiotics Further placebo controlled trials are unethical – Other trials comparing preparations and timing are needed

Luedtke SA, Yang JT, Wild HE: Probiotics and necrotizing enterocolitis: Finding the missing pieces of the probiotic puzzle. The journal of pediatric pharmacology and therapeutics : 2012, 17(4):

How to find a reliable source A preparation identical to one used in an RCT which showed efficacy. – ABCdophilus – (infloran is not available in the US and has changed consituents) A preparation with similar or identical strains and good quality control (a Health Canada NPN for example) – Florababy

Probiotics Babies in North America should be receiving probiotics We have appropriate preparations available The Balance of Benefits and risks is undeniable